Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs announced that management will be participating in three upcoming Fall conferences. The Tharimmune team will present new results at the American College of Gastroenterology (ACG) Annual Scientific Meeting, being held October 24-29, 2025 at the Phoenix Convention Cente ...